Stay updated on Duvelisib in Refractory Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.

Latest updates to the Duvelisib in Refractory Lymphoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedA note was added clarifying that PubMed publications are automatically populated and may not all relate to the study, and the revision label was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check27 days agoChange DetectedNotice about government funding status and NIH operating status has been removed from the page.SummaryDifference0.3%

- Check49 days agoChange DetectedNo substantive changes were detected in the Study Details page for NCT01882803; the core sections including eligibility criteria, primary outcomes, and locations appear unchanged between the screenshots.SummaryDifference0.3%

- Check70 days agoChange DetectedSignificant update: new operating-status notice and version bump to v3.2.0; previous v3.1.0 reference removed.SummaryDifference4%

- Check77 days agoChange DetectedUpdate: citation updated from v3.0.2 to v3.1.0 and addition of an erratum note; essentially a bibliographic metadata precision upgrade rather than a major content change.SummaryDifference0.5%

- Check92 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed; no substantive changes to core content.SummaryDifference0.2%

Stay in the know with updates to Duvelisib in Refractory Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.